Immutrin
PrivateLast Round
Series A
Mar 24, 2026
Total Funding Raised
$87M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Immutrin operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was a Series A round in March 2026.
Immutrin is a biotechnology company that develops antibody therapies designed to deplete systemic amyloid deposits and reverse amyloidosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immutrin Comparables
Compare Immutrin with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Attralus | 80% | |
| AstraZeneca | 74% | |
| Prothena Corporation plc | 74% |
For institutional investors. Book with your work email.
Immutrin Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Immutrin Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cambridge Enterprise Ventures | Series A |
| Frazier Life Sciences | Series A |
| Cambridge Enterprise | Series A |
| Cambridge Innovation Capital | Series A |
| F-Prime Capital | Series A |
| Qiming Venture Partners | Series A |
| SR One | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 20, 2026
Grew 36% QoQ, from 14 to 19 employees.
- Aug 16, 2026
Grew 58% QoQ from 12 to 19 employees.
For institutional investors. Book with your work email.
Immutrin Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Immutrin's valuation, stock price, and market status.
Is Immutrin a public or private company?
Immutrin is a private company.
What is the current stock price of Immutrin?
Immutrin is a private company, so its shares have no public market price. Caplight tracks Immutrin's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Immutrin worth (valuation)?
Valuation information for Immutrin is not publicly available.
Can I buy Immutrin stock?
Immutrin shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Immutrin's last funding round?
Immutrin's most recent funding round was Series A on March 24, 2026.
Who are the main investors in Immutrin?
Key investors in Immutrin include Frazier Life Sciences.
Will Immutrin IPO soon?
No public IPO plans have been announced for Immutrin.
How can I track Immutrin secondary market activity?
Caplight tracks bids, offers, and trades in Immutrin's shares on secondary markets.